Smith & Nephew (SN) Trading Down 0%
Smith & Nephew plc (LON:SN)’s share price traded down 0% on Wednesday . The company traded as low as GBX 1,294 ($17.42) and last traded at GBX 1,300 ($17.50). 3,052,532 shares were traded during mid-day trading, an increase of 6% from the average session volume of 2,890,000 shares. The stock had previously closed at GBX 1,300 ($17.50).
SN has been the subject of several research analyst reports. Berenberg Bank reiterated a “hold” rating and set a GBX 1,340 ($18.03) target price on shares of Smith & Nephew in a research note on Friday, November 3rd. J P Morgan Chase & Co reiterated a “neutral” rating and set a GBX 1,382 ($18.60) target price on shares of Smith & Nephew in a research note on Monday, November 6th. Deutsche Bank increased their target price on Smith & Nephew from GBX 1,200 ($16.15) to GBX 1,315 ($17.70) and gave the company a “hold” rating in a research note on Monday, October 23rd. Jefferies Group reiterated a “buy” rating and set a GBX 1,515 ($20.39) target price on shares of Smith & Nephew in a research note on Thursday, October 12th. Finally, Citigroup reiterated a “sell” rating and set a GBX 1,160 ($15.61) target price on shares of Smith & Nephew in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company. Smith & Nephew currently has an average rating of “Hold” and an average price target of GBX 1,315.82 ($17.71).
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.